ImmunoGen Inc., a Waltham biotechnology company, announced Monday the appointment of Charles Morris as executive vice president and chief development officer.
In that capacity, Morris is responsible for leading all aspects of product development. He reports to Daniel Junius, ImmunoGen’s president and chief executive, the company said in a press release.
Before joining ImmunoGen, Morris was the executive vice president and chief medical officer at Allos Therapeutics Inc.
ImmunoGen currently has three anti-cancer compounds in clinical testing.
In a statement, Junius said: “We now have three wholly owned clinical-stage compounds, expect to advance our fourth product candidate into the clinic in 2013, and have additional highly promising compounds behind these in our pipeline. We are excited to have Charlie joining ImmunoGen at this important time in our transition to being a product development company.”